Advertisement
New Zealand markets closed
  • NZX 50

    11,931.32
    -2.99 (-0.03%)
     
  • NZD/USD

    0.5964
    -0.0035 (-0.59%)
     
  • NZD/EUR

    0.5590
    +0.0002 (+0.03%)
     
  • ALL ORDS

    8,050.20
    -23.90 (-0.30%)
     
  • ASX 200

    7,788.10
    -25.50 (-0.33%)
     
  • OIL

    85.97
    +0.95 (+1.12%)
     
  • GOLD

    2,409.70
    +37.00 (+1.56%)
     
  • NASDAQ

    18,307.98
    +296.33 (+1.65%)
     
  • FTSE

    8,011.67
    +87.87 (+1.11%)
     
  • Dow Jones

    38,459.08
    -2.43 (-0.01%)
     
  • DAX

    18,093.00
    +138.52 (+0.77%)
     
  • Hang Seng

    16,721.69
    -373.34 (-2.18%)
     
  • NIKKEI 225

    39,523.55
    +80.92 (+0.21%)
     
  • NZD/JPY

    91.3670
    -0.5140 (-0.56%)
     

The Zacks Analyst Blog Highlights Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic

For Immediate Release

Chicago, IL – February 28, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. LLY, The Procter & Gamble Co. PG, Morgan Stanley MS, AT&T Inc. T and Medtronic plc MDT.

Here are highlights from Tuesday’s Analyst Blog:

Top Analyst Reports for Eli Lilly, Procter & Gamble and Morgan Stanley

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., The Procter & Gamble Co. and Morgan Stanley. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Eli Lilly's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+150.1% vs. +37.0%). The company's revenue growth is being driven by higher demand for drugs like Mounjaro, Verzenio, Jardiance Taltz and others.

Lilly's new FDA-approved tirzepatide medicines, diabetes drug Mounjaro and newly launched weight loss medicine, Zepbound, are expected to be key top-line drivers. Lilly has also launched some other new products recently like Omvoh and Jaypirca. These new products are expected to drive Lilly's top line in 2024.

Lilly is also making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. However, generic competition for some drugs, rising pricing pressure and challenges in meeting strong demand for incretin products like Trulicity are some top-line headwinds.

(You can read the full research report on Eli Lilly here >>>)

Shares of Procter & Gamble have outperformed the Zacks Soap and Cleaning Materials industry over the past year (+19.4% vs. +15.9%). The company has been gaining from robust pricing and a favorable mix, along with strength across segments.

Procter & Gamble has been focused on productivity and cost-saving plans to boost margins. This led to the top and bottom lines beating the consensus mark for the fifth consecutive quarter in the first quarter of fiscal 2024. Consequently, PG has provided an optimistic fiscal 2024 view.

However, the company has been witnessing supply-chain issues, higher SG&A costs, higher transportation costs and rising inflation. Its significant international presence exposes it to foreign currency risks, which acts as a headwind.

(You can read the full research report on Procter & Gamble here >>>)

Morgan Stanley's shares have gained +3.7% over the past six months versus the Zacks Financial - Investment Bank industry's gain of +13.3%. The company's new strategic alliance with Mitsubishi UFJ will bolster its presence in Japan. Further, the company's initiatives to become less dependent on capital-markets-driven revenue sources, inorganic growth efforts and high interest rates will support the top line.

However, the ambiguity of the performance of the capital markets is a woe and is expected to hurt the Institutional Securities segment's prospects. Elevated operating expenses due to inflation and the company's investments in franchise are likely to hamper profitability.

(You can read the full research report on Morgan Stanley here >>>)

Other noteworthy reports we are featuring today include AT&T Inc. and Medtronic plc.

ADVERTISEMENT

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                       

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Morgan Stanley (MS) : Free Stock Analysis Report

AT&T Inc. (T) : Free Stock Analysis Report

Procter & Gamble Company (The) (PG) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Medtronic PLC (MDT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research